Two Positive Nodes Represent a Significant Cut-off Value for Cancer Specific Survival in Patients with Node Positive Prostate Cancer. A New Proposal Based on a Two-Institution Experience on 703 Consecutive N+ Patients Treated with Radical Prostatectomy, Extended Pelvic Lymph Node Dissection and Adjuvant Therapy

Briganti, Alberto; Karnes, Jeffrey; Pozzo, L. Da; Cozzarini, C.; Gallina, Andrea; Suardi, Nazareno; Bianchi, Marco; Freschi, Massimo; Doglioni, Claudio; Fazio, Ferruccio; Rigatti, Patrìzio; Montorsi, Francesco; Blute, Michael L.

doi:10.1016/j.eururo.2008.09.043

Cited by 274 publications

(177 citation statements)

References 24 publications

Supporting

Mentioning

158

Contrasting

Unclassified

Order By: Relevance

“…Кроме того, существуют данные, свидетельствующие о том, что выполнение расширенной тазовой лимф-аденэктомии (рТЛАЭ) у больных с наличием лимфо-генных метастазов и низкой плотностью метаста-тического поражения тазовых ЛУ может иметь терапевтическое значение [24]. Исследования показа-ли, что выполнение рТЛАЭ у ряда больных РПЖ про-межуточного и высокого риска прогрессирования позволяет улучшить показатели безрецидивной био-химической, а в ряде случаев и общей выживаемости [25,26]. В связи с этим возникло предположение, что выполнение спасительной лимфаденэктомии (ЛАЭ) у больных с клиническим прогрессированием РПЖ и метастазами в ЛУ может являться рациональ-ным методом лечения тщательно отобранной когорты пациентов.…”

Section: диагностика и лечение опухолей мочеполовой системы рак предunclassified

Methods for the diagnosis and treatment of oligometastases in patients with prostate cancer and progressive disease after radical treatment

Алексеев¹,

Нюшко²,

Krasheninnikov³

et al. 2016

Cancer Urology

View full text Add to dashboard Cite

Section: диагностика и лечение опухолей мочеполовой системы рак предunclassified

Methods for the diagnosis and treatment of oligometastases in patients with prostate cancer and progressive disease after radical treatment

Алексеев¹,

Нюшко²,

Krasheninnikov³

et al. 2016

Cancer Urology

View full text Add to dashboard Cite

“…In this context, previous investigations reported that the survival of patients with node-positive disease is not invariably poor [20] . This is true even when considering patients who experience disease recurrence after primary treatment [21,22] . For example, it has been hypothesized that patients with nodal recurrence after surgery might benefit from local tumor control, such as salvage lymph node dissection, in terms of clinical-recurrence free survival [22,23] .…”

Section: Introductionmentioning

confidence: 98%

Beyond the Bone: Atypical Metastases in Prostate Cancer

Gandaglia

Karakiewicz²,

Sun³

2014

Cancer Cell Microenviron

View full text Add to dashboard Cite

The bone represents the most common site of metastases in patients with prostate cancer (PCa). However, the proportion of men experiencing atypical metastatic sites, defined as the metastases localizing to sites other than bones or lymph nodes outside the pelvis or abdomen, is significant. For example, 10.6%, 10.2% and 9.1% of patients with metastatic PCa experience distant lymph nodes, liver, and thorax involvement, respectively. The knowledge of the distribution of metastatic sites can help provide physicians with better staging strategies, as well as follow-up protocols aimed at a prompt diagnosis of tumor recurrence after primary treatment. The involvement of atypical sites of metastases might also have a prognostic value, where individuals with visceral metastases experience shorter survival compared to their counterparts with exclusive bone involvement. Consequently, this parameter should be taken in account during the decision-making process in the treatment of PCa patients.

show abstract

“…The inclusion of biopsy-derived information is very important when predicting LNI due to the predictive value of percentage positive cores for nodal metastases [Briganti et al 2012]. While acknowledging that the use of lymphadenectomy in PCa is a controversial point [Briganti et al 2009a[Briganti et al , 2009bMiki and Egawa, 2011;Spahn et al 2010], some believe that lymphadenectomy can be curative. However, more data are needed to confirm this belief.…”

Section: Identifying Individualizing and Improving Patient Carementioning

confidence: 99%

Controversies on individualized prostate cancer care: gaps in current practice

Joniau¹,

Pfister

Taille

et al. 2013

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Prostate cancer (PCa) is a heterogeneous disease with a wide spectrum of aggressiveness. Evidence-based guidelines are invaluable but cannot be expected to be extensive enough to provide detailed guidance on the management of all patients. As such, the use of individualized, risk-adapted approaches to the management of PCa is indispensable. However, wide variation in treatment approaches observed for patients in practice suggests that there is an unmet need to improve the individualized approach towards patient care. A holistic approach that encompasses guidelines and evidence-based medicine could be used to guide individualized care for patients with PCa, from first contact through to final outcomes. As a result of an international expert meeting, this paper proposes this approach and highlights some of the factors that can be considered when aiming to identify patients' profiles; individualize treatment; and improve communication between patients and the healthcare teams.

show abstract

Cited by 274 publications

References 24 publications

Methods for the diagnosis and treatment of oligometastases in patients with prostate cancer and progressive disease after radical treatment

Methods for the diagnosis and treatment of oligometastases in patients with prostate cancer and progressive disease after radical treatment

Beyond the Bone: Atypical Metastases in Prostate Cancer

Controversies on individualized prostate cancer care: gaps in current practice

Contact Info

Product

Resources

About